Forbes contributors publish independent expert analyses and insights. I show you how to save and invest. The Federal Open Market Committee is expected to move interest rates lower in 2026, but not ...

Adam Palasciano is a writer over three years of experience writing about personal finance, investing, student loans, and more, for outlets like GOBankingRates, FinanceBuzz, The Penny Hoarder, and Wall ...

Monitoring the interest rate climate for homebuyers and owners hoping to refinance can easily become a daily activity. And in the interest rate climate of recent years, it was often a disappointing ...

In east Tennessee, at the end of a winding dirt road, a mother glances into the woods she roamed as a child. It’s a deep and dramatic vista: a patchwork of pines and oaks disappearing into an endless ...

Colin is an Associate Editor focused on tech and financial news. He has more than three years of experience editing, proofreading, and fact-checking content on current financial events and politics.

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

The Federal Reserve's recent 0.25% interest rate cut may make it cheaper for consumers to take out large loans. A lower interest rate can reduce the total amount paid on a car loan over its term, ...

Federal Reserve Chair Jerome Powell hinted interest rate cuts could be coming soon in a speech on Friday, a move that could affect everyone from global markets to individual Americans. Powell ...

Allowing your money to grow over time is one of the best ways to build wealth. It's possible to reach $1 million by steadily investing a portion of your income. Most experts recommend saving 15% of ...

Rallybio has agreed to sell its interest in a drug-development plan seeking to treat a rare genetic bone disease to its joint-venture partner Recursion Pharmaceuticals for up to $25 million. The New ...